Learn how Pfizer’s clinical research aims to help advance the treatment of prostate cancer.

Pfizer continues to strive for potential treatment options that may offer new hope for men with prostate cancer. As with many potential treatments, our goal is to help prevent the cancer from advancing further and to improve life expectancy.

We are evaluating study medicines in clinical trials that focus mostly on advanced types of prostate cancer, such as castration-sensitive or castration-resistant prostate cancer. (Learn more about these types of prostate cancer at the bottom of the page.) These studies are researching a study medicine taken along with a currently available standard treatment.

If you or a loved one are considering taking part in a prostate cancer clinical trial, find more information below.

Refine your search

Find a prostate cancer clinical trial

Refine your search by applying one of these filters.

Search
    Location
      Age (years)
      Sex

      Show filters

      6 trials found

      All(6)
      Recruiting(5)
      Not yet recruiting(1)
      2 trials recruiting
      MEVPRO Prostate Cancer Clinical Trials

      Clinical trials exploring mevrometostat as a potential treatment for metastatic prostate cancer.

      Recruiting
      NCT06629779
      A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

      Metastatic Castration-Resistant Prostate Cancer

      Males
      18+ years
      60study location(s)
      Recruiting
      NCT06551324
      A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

      Metastatic Castrate Resistant Prostate Cancer (mCRPC)

      Males
      18+ years
      68study location(s)
      Recruiting
      NCT04557449
      Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

      Liposarcoma, Prostate Cancer, Breast Neoplasms, Adenocarcinoma of Lung

      Male or Female
      18+ years
      92study location(s)
      Recruiting
      NCT03460977
      Mevrometostat Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

      Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL)

      Male or Female
      18+ years
      136study location(s)
      Recruiting
      NCT04606446
      Study of PF-07248144 in Advanced or Metastatic Solid Tumors

      Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer

      Male or Female
      18+ years
      106study location(s)
      Dec 16, 2024 - Planned start date (Not yet recruiting)
      NCT06650579
      REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial

      Recurrent Prostate Carcinoma, Stage III Prostate Cancer AJCC V8, Stage IVA Prostate Cancer AJCC V8

      Males
      18+ years
      4study location(s)

      Saved trials

      Saved trials

      You currently don’t have any saved trials. To save a trial, select the bookmark icon on the result listing.

      All(6)
      Recruiting(5)
      Not yet recruiting(1)

      Contact us

      For more information about participation in a Pfizer clinical trial, please email or call the Pfizer Clinical Trial Contact Center at 1-800-887-7002.


      About prostate cancer

      Prostate cancer occurs when the cells within the prostate gland start to multiply out of control. It is the second most common cancer in American men, after skin cancer.

      When prostate cancer has not spread beyond the prostate, treatment may first involve surgery or radiation to remove the cancer. Initial treatment may also involve medication that aims to keep levels of the male sex hormones low. This is because prostate cancer growth is often driven by male sex hormones, including testosterone.

      Metastatic castration sensitive prostate cancer occurs when the cancer spreads to other parts of the body, or if the cancer is first diagnosed when it has already spread. This type of prostate cancer is still responsive to hormone therapy.

      If hormone therapy no longer stops or slows the cancer, the condition is known as metastatic castration resistant prostate cancer.